Last $22.43 USD
Change Today -1.11 / -4.72%
Volume 387.7K
FMI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

foundation medicine inc (FMI) Snapshot

Open
$23.95
Previous Close
$23.54
Day High
$23.95
Day Low
$22.22
52 Week High
03/19/14 - $45.00
52 Week Low
10/1/14 - $18.25
Market Cap
635.0M
Average Volume 10 Days
192.3K
EPS TTM
$-1.87
Shares Outstanding
28.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FOUNDATION MEDICINE INC (FMI)

foundation medicine inc (FMI) Related Bloomberg News

View More Bloomberg News

foundation medicine inc (FMI) Related Businessweek News

View More BusinessWeek News

foundation medicine inc (FMI) Details

Foundation Medicine, Inc. provides various molecular information products in the United States. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. The company offers clinical products, such as FoundationOne for solid tumors; and FoundationOne Heme, for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers. It has strategic collaboration agreement with WuXi PharmaTech (Cayman) Inc. to provide genomic profiling to biopharmaceutical companies conducting clinical trials. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts.

186 Employees
Last Reported Date: 03/7/14
Founded in 2009

foundation medicine inc (FMI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $403.9K
Chief Operating Officer
Total Annual Compensation: $336.8K
Chief Medical Officer
Total Annual Compensation: $342.5K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $330.0K
Senior Vice President and General Counsel
Total Annual Compensation: $178.5K
Compensation as of Fiscal Year 2013.

foundation medicine inc (FMI) Key Developments

Foundation Medicine's Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology's PARP Inhibitor, Rucaparib

Foundation Medicine, Inc. announced the presentation of new data from its ongoing collaboration with Clovis Oncology to develop a novel companion diagnostic test to identify patients who have the potential to benefit from rucaparib, Clovis Oncology's poly (ADP-ribose) polymerase inhibitor (PARPi). These new data suggest that Foundation Medicine's novel companion diagnostic can identify both BRCA-mutant patients and non BRCA-mutant patients who are more likely to benefit from rucaparib than patients who are biomarker negative. The interim findings, being presented in an oral plenary session at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, are the first reported clinical data from ARIEL2 (Assessment of Rucaparib In Ovarian Cancer Trial), a single-arm, open-label Phase 2 study currently enrolling patients with relapsed, platinum-sensitive ovarian cancer. The study demonstrated an overall response rate of 70% in BRCA-mutant patients; these responses were observed in both germline and somatic BRCA-mutant tumors. Notably, 40% of patients identified by Foundation Medicine's companion diagnostic as not BRCA-mutant, but with a "BRCAness" signature demonstrated a response to rucaparib, versus only 8% of patients without the signature, suggesting a potentially expanded group of patients who may benefit from rucaparib therapy. Rucaparib has previously demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations; however, predicting response to a PARPi beyond tumors harboring germline BRCA1/2 mutations is a key challenge. Clovis Oncology and Foundation Medicine have partnered to develop a comprehensive genomic profiling-based assay to identify patients with BRCA1/2 mutations in tumor tissue, as well as those with a "BRCAness" signature, a tumor demonstrating homologous recombination deficiency (HRD) due to mechanisms other than a BRCA1/2 mutation. The test, which will be submitted for FDA premarket approval, assesses all classes of genomic alterations, and utilizes advanced bioinformatics based on Foundation Medicine's molecular information platform, to identify women with ovarian cancer who are more likely to respond to rucaparib. Key findings include: Foundation Medicine's novel companion diagnostic test can identify ovarian cancer patients who are likely to respond to rucaparib by assessing all relevant BRCA1/2 mutations and a BRCAness signature in tumor tissue samples; Overall response rate (ORR) of 70% in BRCA-mutant patients; responses observed in patients with both germline and somatic mutations; ORR of 40% in patients with BRCAness signature; ORR of only 8% in patients without BRCA1/2 mutation or BRCAness signature; Approximately 67% of patients treated to date exhibit BRCA-ness signature or BRCA-mutant status; Rucaparib is well-tolerated; no drug discontinuations due to treatment-related adverse events; and molecular tumor analysis may identify a broad selection of ovarian cancer patients who could benefit from rucaparib therapy.

Foundation Medicine, Inc. Presents at Goldman Sachs Group 2014 US Emerging / SMID Cap Growth Conference, Nov-20-2014 02:20 PM

Foundation Medicine, Inc. Presents at Goldman Sachs Group 2014 US Emerging / SMID Cap Growth Conference, Nov-20-2014 02:20 PM. Venue: New York Marriott Marquis, New York, New York, United States. Speakers: Michael J. Pellini, Chief Executive Officer, President and Director.

Foundation Medicine, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 10:30 AM

Foundation Medicine, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 10:30 AM. Venue: The Westin Grand Central, New York, New York, United States. Speakers: Jason Ryan, Senior Vice President of Finance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FMI:US $22.43 USD -1.11

FMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genomic Health Inc $33.17 USD +0.74
NeoGenomics Inc $4.36 USD -0.13
Response Genetics Inc $0.55 USD +0.03
Rosetta Genomics Ltd $2.53 USD +0.15
Sequenom Inc $2.90 USD +0.04
View Industry Companies
 

Industry Analysis

FMI

Industry Average

Valuation FMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.1x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOUNDATION MEDICINE INC, please visit www.foundationmedicine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.